Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) Short Interest Up 29.8% in January

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 85,580 shares, an increase of 29.8% from the January 15th total of 65,924 shares. Based on an average daily volume of 69,840 shares, the short-interest ratio is presently 1.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 69,840 shares, the short-interest ratio is presently 1.2 days.

Sandoz Group Stock Up 0.0%

Shares of SDZNY opened at $85.73 on Monday. The company has a current ratio of 1.29, a quick ratio of 0.82 and a debt-to-equity ratio of 0.62. Sandoz Group has a twelve month low of $35.61 and a twelve month high of $86.80. The business’s 50-day moving average price is $76.52 and its 200-day moving average price is $67.61.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Strong Buy”.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.